Responsibility

Overview

Group 350

At Ironwood, we have been steadfast in our mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We have long believed that how we do things is just as important as what we do.

Our culture is one that prioritizes sustainability in everything we do. From recruiting and retaining our talented employees, to overseeing our internal processes, to remaining mindful of our environmental footprint daily, we know that delivering on our mission requires taking a broad view of success—one that must be measured against the backdrop of corporate social responsibility and sustainability.

Dear Stakeholders,

At Ironwood, we have been steadfast in our mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We have long believed that how we do things is just as important as what we do.

That principle has never been more critical, as the COVID-19 pandemic has presented unprecedented challenges to us all.

Our team has displayed great resilience throughout the pandemic, working tirelessly to advance the treatment of GI diseases and redefine the standard of care for GI patients while readily adapting to a new, largely remote way of working in 2020 and 2021. We are immensely proud that we continued to advance our research and development efforts and achieved blockbuster commercial success with LINZESS®, which surpassed $1 billion in U.S. net sales in 2021 and reached more than 3.5 million U.S. patients.

Underpinning our success is our strong investment in a culture that prioritizes sustainability in everything we do. From recruiting and retaining our talented employees, to overseeing our internal processes, to remaining mindful of our environmental footprint on a daily basis, we know that delivering on our mission requires taking a broad view of success. While stockholder value remains our essential guidepost, we must always measure our performance against the backdrop of corporate social responsibility and sustainability.

These are things that we have done because it is core to who we are. Now, companies across all industries are being challenged to innovate and create more value while strengthening environmental, social, and governance (ESG) performance. For Ironwood’s inaugural ESG Report, we embarked on a comprehensive company-wide project to identify our high-priority ESG issues and capture our progress and commitment.

In it, we highlight key Ironwood initiatives and philosophies that support our sustainability efforts. I’m extremely proud of the progress we’re making and of the people who have worked hard to make our vision of an inclusive, ethical and responsible culture a reality. As we look to the future of Ironwood, we do so with hope for a brighter tomorrow that continues to elevate our ESG goals and priorities.

Sincerely,

Thomas McCourt
iw-ESG-2021
Thomas McCourt

Chief Executive Officer & Director

Ironwood has successfully completed the tender offer of VectivBio, a global clinical-stage biotechnology company
pioneering novel, transformational treatments for severe rare gastrointestinal conditions. For more information, click here